> SIRT > Home > Experts group




The Selective Internal Radiation Therapy Experts Group, is an initiative set up by practising clinicians who have many years of therapeutic experience and dedicated to the rapid and effective SIRT treatment of patients with tumours or metastases of the liver.


Its objectives are:


  • To make the general public aware of the treatment and its advantages.
  • To provide interested parties with comprehensive and reliable information about SIRT.
  • To make sufferers’ prompt access to SIRT treatment easier through a network of experts across Germany.



Members of the Selective Internal Radiation Therapy Experts Group:

Prof. Thomas Berg
Head of the Hepatology Unit within the Department of Gastroenterology and Rheumatology at the University Hospital of Leipzig

Prof. Thomas Berg

Download CV of Prof. Thomas Berg

PD Dr Benjamin Garlipp
Senior Physician for Visceral Surgery, Surgical Department of Oberhavel-Kliniken, Hennigsdorf

Dr Benjamin Garlipp

Download CV of Dr Benjamin Garlipp

Dr Oliver Marschal
Specialist in General and Palliative Medicine, Oncology Practice of Doctors M. Adler, O. Marschal and A. Pies, Braunschweig

Dr Oliver Marschal

Download CV Dr Oliver Marschal

PD Dr Marlies Michl
Specialist in General Medicine, Haematology and Medical Oncology at the Department of Medicine and Outpatients III, Munich University Hospital

Dr Marlies Michl

Download CV of PD Dr Marlies Michl

Prof. Jens Ricke
Director of the Department of Radiology, University Hospital of Munich

Prof. Jens Ricke

Download CV of Prof. Jens Ricke

Prof. Hans Scherübl
Clinical Lead of the Department of General Medicine, Gastroenterology and Gastrointestinal Oncology, Vivantes Klinikum am Urban, Berlin

Prof. Hans Scherübl

Download CV of Prof. Hans Scherübl

Prof. Klaus Tatsch
Director of the Department of Nuclear Medicine, Städtisches Klinikum Karlsruhe

Prof. Klaus Tatsch

Download CV of Prof. Klaus Tatsch

More treatment options are necessary for patients with metastatic colorectal cancer – Colorectal cancer prevention is getting more and more attention. However, every third colorectal cancer patient develops metastases in the course of the disease – often in the liver. For these patients, more and better therapy options are needed. Local therapies offer promising opportunities.To the press release
The new ESMO guidelines recommend SIRT for people with metastatic colorectal cancer if the metastases are limited to the liver and are not responding to chemotherapy.
New evidence of the benefits of SIRT in mCRC – The depth-of-response data from the SIRFLOX study shows a significantly larger local depth of response through the combination of SIRT and chemotherapy. To the press release
Metastatic colorectal cancer: the SIRFLOX, FOXFIRE and FOXFIRE Global studies are investigating the benefits of combining SIRT with chemotherapy. The data from the three studies regarding overall survival is expected by the end of 2017. The SARAH and SIRveNIB studies on advanced liver cell cancer are now complete. Both compared Y90 radio-embolisation with sorafenib chemotherapy. The initial results are set to be published at the end of 2016 (SARAH) and 2017 (SIRveNIB).
The SIRT Experts Group is a partner of: